Literature DB >> 25075161

A Randomized Comparison between Everolimus-Eluting Stent and Cobalt Chromium Stent in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Using Routine Intravenous Eptifibatide: The X-MAN (Xience vs. Multi-Link Stent in Acute Myocardial Infarction) Trial, A Pilot Study.

Surya Dharma1, Alexander J Wardeh2, Sunarya Soerianata1, Isman Firdaus1, J Wouter Jukema3.   

Abstract

The objective of this study is to determine the efficacy and safety of an everolimus-eluting stent (EES/Xience; Abbott Vascular, Santa Clara, CA) compared with a cobalt chromium stent (CoCr/Multi-Link Vision; Abbott Vascular) in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) with routine administration of eptifibatide infusion. This is a prospective, single center, randomized trial comparing EES (n = 75) and CoCr stent (n = 75) implantation in patients with acute STEMI undergoing primary PCI. Intravenous eptifibatide administration was mandatory by protocol in this pilot study. The primary efficacy endpoint was major adverse cardiac events (MACE) at 30 days, defined as the composite of death, reinfarction, and target vessel revascularization. Secondary safety endpoints were stent thrombosis at 30 days and in-hospital bleeding event. Acute reperfusion parameters were also assessed. One-month MACE rate did not differ between EES and CoCr group (1.3 vs. 1.3%, p = 1.0). No stent thrombosis cases were observed in the EES group. The groups did not differ with respect to in-hospital bleeding events (5 vs. 9%, p = 0.37), achievement of final thrombolysis in myocardial infarction flow 2 or 3 (p = 0.21), achievement of myocardial blush grade 2 or 3 (p = 0.45), creatine kinase-MB level at 8 to 12 hours after stenting (p = 0.29), and left ventricular ejection fraction (p = 0.21). This pilot study demonstrates that after one-month follow-up, the use of EES is as safe and effective as the use of CoCr stents in patients with acute STEMI undergoing primary PCI with routine administration of intravenous eptifibatide.

Entities:  

Keywords:  STEMI; cobalt chromium; eptifibatide; everolimus; primary PCI; stent

Year:  2014        PMID: 25075161      PMCID: PMC4082456          DOI: 10.1055/s-0033-1356649

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  33 in total

Review 1.  Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction.

Authors:  Bindu Kalesan; Thomas Pilgrim; Katja Heinimann; Lorenz Räber; Giulio G Stefanini; Marco Valgimigli; Bruno R da Costa; François Mach; Thomas F Lüscher; Bernhard Meier; Stephan Windecker; Peter Jüni
Journal:  Eur Heart J       Date:  2012-02-23       Impact factor: 29.983

Review 2.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

Authors:  Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting
Journal:  Catheter Cardiovasc Interv       Date:  2012-02-15       Impact factor: 2.692

Review 3.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

4.  The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.

Authors:  Eberhard Grube; Bernard Chevalier; Peter Smits; Vladimir Džavík; Tejas M Patel; Ajit S Mullasari; Jochen Wöhrle; Marrianne Stuteville; Cécile Dorange; Upendra Kaul
Journal:  JACC Cardiovasc Interv       Date:  2011-02       Impact factor: 11.195

5.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

Authors: 
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

6.  3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).

Authors:  Scot Garg; Patrick Serruys; Yoshinobu Onuma; Cécile Dorange; Susan Veldhof; Karine Miquel-Hébert; Krishnankutty Sudhir; Jean Boland; Kurt Huber; Eulogio Garcia; Jan A M te Riele
Journal:  JACC Cardiovasc Interv       Date:  2009-12       Impact factor: 11.195

Review 7.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

8.  Non-invasive assessment of infarct reperfusion: the predictive power of the time to peak value of myoglobin, CKMB, and CK in serum.

Authors:  H A Katus; K W Diederich; T Scheffold; M Uellner; F Schwarz; W Kübler
Journal:  Eur Heart J       Date:  1988-06       Impact factor: 29.983

9.  Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis.

Authors:  M Dalby; A Bouzamondo; P Lechat; G Montalescot
Journal:  Circulation       Date:  2003-10-06       Impact factor: 29.690

10.  Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study.

Authors:  Bas L van der Hoeven; Su-San Liem; J Wouter Jukema; Navin Suraphakdee; Hein Putter; Jouke Dijkstra; Douwe E Atsma; Marianne Bootsma; Katja Zeppenfeld; Pranobe V Oemrawsingh; Ernst E van der Wall; Martin J Schalij
Journal:  J Am Coll Cardiol       Date:  2008-02-12       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.